DFTX-301

About Definium Therapeutics

Definium Therapeutics is a public biotech company dedicated to translating innovative science into transformative medicines for patients with cancer and immune disorders. Its core strategy involves targeting key disease-driving pathways that have eluded conventional drug discovery approaches. The company's lead asset is in Phase 1/2 development, supported by a robust preclinical pipeline and a strong intellectual property portfolio. Definium aims to establish itself as a leader in precision oncology and immunology through strategic clinical execution and potential partnerships.

Therapeutic Areas

Other Hematological Malignancies Drugs